Radiochemical studies and biological evaluation in animal models have shown superior radiochemical properties and better clearance pattern for ¹⁷⁷Lu-DOTMP compared with ¹⁷⁷Lu-EDTMP, an agent recently proven to be efficacious and safe for metastatic bone pain palliation. This prompted us to initiate the clinical evaluation of ¹⁷⁷Lu-DOTMP. The images represent the whole-body scans of a prostate cancer patient (man, 67 years) with skeletal metastases recorded after administering 3.7 GBq (100 mCi) of ¹⁷⁷Lu-DOTMP.